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ABSTRACT  
OBJECTIVES : 
Primary outcome:                 
To determine the optimal comfort and co-operation among the patients for 
Awake fiberoptic intubation procedural sedation.                 
Secondary outcome: 
 
           Ease of intubation, intubation time, sedation scale, comfort scores and  
hemodynamic variables. 
DESIGN : 
           Single centre, prospective, randomized, parallel group, double blinded  
Study. 
SETTING : 
         Department of Anaesthesiology, Tirunelveli Medical College,  
Tirunelveli. 
SUBJECT : 
         40 patients of both sexes in the age group of 25 to 50  belonging to ASA  
I and II status undergoing thyroid surgery. 
METHODS : 
          After randomization and masking all the subjects in the group were subjected to 
premedicant Inj.Glycopyrrolate and topical  anaesthesia for the airway . Group D 
received 1 mcg/kg of  dexmedetomidine followed by an infusion of  0.7 mcg/kg/hr 
whereas group FM received 2 mcg/kg of  fentanyl and 40 mcg/kg of midazolam. 
 
MONITORING :    
          Patient was monitored for Vital parameters , sedation score based on Ramsay 
sedation scale , Comfort scores based on ambu et al scoring , intubation scores.  
ANALYSIS & RESULTS : 
          After recording in the master sheet, data was analysed using SPSS software, 
Sigma stat 3.5 version by means of student t test, one way ANOVA and chi square 
test. Stastical significance existed between two groups in terms of intubation time 
(P<0.001), sedation scale (P<0.005), comfort scores (P<0.001), hemodynamic 
variables  (P<0.02) and SPO2 scores (P<0.02), with dexmedetomidine being the better 
drug among the two. Rest of the variables were comparable but not significant. 
CONCLUSION : 
          Dexmedetomidine offered a good sedation, amnesia, anxiolysis,  analgesia, 
shorter intubation time  and a better hemodynamics avoiding respiratory depression 
when compared with fentanyl midazolam combination.  
KEYWORDS : 
Dexmedetomidine hydrochloride, intubation, fentanyl citrate, sedation, midazolam . 
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INTRODUCTION 
 
                   Fiberoptic nasotracheal intubation is one of the techniques available for 
the management of patients with difficult airways.  Fiberoptic and video technologies 
are widely used for airway management at recent times. The term ‘AFOI’ is used to 
distinguish this procedure from fiberoptic intubation performed under general 
anesthesia. 
                  Awake fiberoptic intubation (AFOI) is indicated for patients with 
anticipated difficult airways because of their anatomy, airway trauma, morbid obesity, 
and unstable cervical spine injuries. One challenge associated with this procedure is 
providing adequate sedation and anxiolysis while maintaining a patent airway and 
adequate ventilation, especially with difficult or critical airways. Optimal intubating 
condition with sedation and patient comfort are important factor and a great challenge 
for fiberoptic nasal intubation. Hence there is need for an ideal sedation regimen 
which would provide patient comfort, blunting of airway reflexes, patient cooperation, 
haemo-dynamic stability, amnesia and maintenance of a patent airway with 
spontaneous ventilation. The main goal of conscious sedation for the patient is that he 
has to be awake, calm and cooperative, following our verbal commands. Thus 
conscious sedation minimizes awareness of the procedure and improves patient 
satisfaction.  
 
                      Various drugs may be available to carry out the procedure of which 
midazolam, fentanyl combination is one among them. Midazolam at a dose of 40 mcg/ 
kg provides adequate sedation, anxiolysis and amnesia for the patient. Fentanyl at a 
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dose of 2 mcg/kg relieves pain if any during the procedure and depresses airway 
reflexes which facilitate airway instrumentation. Unfortunately, this combination of 
drugs can cause respiratory depression, placing the patient at risk for hypoxemia and 
aspiration. 
Dexmedetomidine however has several unique properties that make it ideally 
suited for the management of difficult airways. First, it provides an unique form of 
sedation in which patients appear to be sleepy but, if stimulated, are easily aroused, 
cooperative, and communicative. Second, dexmedetomidine has anxiolytic, amnestic, 
and moderate analgesic effects, as well as antisialagogue effects. Third, 
dexmedetomidine has a respiratory-escape effect, even when administered in large 
doses. 
                   In view of the above said statements, we carried out a randomized study to 
investigate the better drug among the two groups for conducting awake fibreoptic 
intubation for which we chose to divide the patients into two groups, one receiving 
fentanyl midazolam combination, and the other one receiving dexmedetomidine. We 
aimed to derive a comprehensive and integrated picture of the relative safety and 
effectiveness of one drug over the other. 
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AIM & OBJECTIVE  
 
 
 
AIM : 
 
                To compare the effectiveness and safety of dexmedetomidine with a 
combination of fentanyl and midazolam for procedural sedation during awake 
fibreoptic intubation. 
 
 
OBJECTIVE: 
 
Primary outcome:                 
To determine the optimal comfort and co-operation among the patients for 
AFOI procedural sedation.                 
Secondary outcome: 
 
          Ease of intubation, intubation time, sedation scale, comfort scores and 
hemodynamic variables. 
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REVIEW OF LITERATURE 
 
                      Shah B.K et al [1] compared the efficacy of Dexmedetomidine with 
midazolam for sedating cardiac patients undergoing awake fibreoptic nasal intubation 
and they concluded that dexmedetomidine is more efficacious than midazolam by 
means of better hemodynamic support and comfort scores for AFOI. 
                        Samia M. Masoud et al [2] studied Dexmedetomidine with  
Conventionally used Propofol/Midazolam and Fentanyl/Midazolam combinations for 
conscious sedation during awake fibrotic intubation. They came to a conclusion that 
Dexmedetomidine was the better drug among the three providing better condition for 
the patient throughout the procedure satisfying their needs. 
                         Tsai et al [3] compared the effectiveness of Dexmedetomidine with 
target controlled infusion of propofol for sedation during fibreoptic nasal intubation. 
They found dexmedetomidine by all means provided better comfort and safety to the 
patient than propofol group. 
                        David cateno et al [4] carried out a randomized double blinded pilot 
study to compare the efficacy of dexmedetomidine with remifentanil for AFOI in a 
group of 30 patients after proper adequate topical anaesthesia and anxiolysis with 2 
mg of midazolam. They came to a conclusion that dexmedetomidine is a better drug 
when compared with remifentanil for AFOI but dependent on dosage and time.  
                      Sunil kumar sinha et al [5] conducted a study to compare  
dexmedetomidine alone with dexmedetomidine & ketamine combination for awake 
nasal fibreoptic intubation in 60 adult patients in the age group of 20 to 60 years with 
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ASA I & II status posted for elective surgery under general anaesthesia. Patients were 
divided into two groups randomly and blinded along with investigator. It was 
concluded that dexmedetomidine ketamine combination offered better hemodynamic 
stability and sedation than dexmedetomidine alone.  
                         Kumkum Gupta et al [6] conducted a randomized clinical trial  
involving 50 patients with temporo mandibular joint ankylosis with an aim of  
determining whether Dexmedetomidine can be used as  a premedicant for awake nasal 
fibreoptic intubation. They concluded that fibreoptic intubation was easier when 
dexmedetomidine was given as a premedicant and also there was a better 
hemodynamic stability. 
                         Xing yung he et al [7] conducted a clinical study using  
dexmedetomidine in patients undergoing AFOI and concluded that  dexmedetomdine 
is a very useful adjunct for the same . 
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AIRWAY ANATOMY 
 
                      The anatomy and physiology of the airway is one of the core topic in  
anaesthesia which needs a detailed discussion  . Ribcage protects the complicated and 
delicate organ, lungs by safely encasing it for carrying out its very precise bodily 
functions. Airway, the passage commencing from the nostrils and ending at alveoli 
plays important functions which are very essential. We the anaesthesiologists work on 
this passage interfering with the normal homeostasis as a result of which we should 
give undue respect for it allowing it to carry out its normal physiologic functions. 
 
                      Nasal sepum divides the nasal cavity into two halves and it consists of 
quadrilateral cartilage joining the vomer and ethmoid bone. On the anterior most part 
of nasal cavity lies the vestibule which is covered by hair and skin following which 
the nasal valves are present which seperates the nasal cavity from vestibule. Posterior 
most part of the nasal septum contains a strut called columella. The roof of nose is tent 
shaped whereas the floor runs in horizontal direction parallel to the hard palate The 
cribriform plate of ethmoid bone forms the middle third of roof of nose, on which lies 
the olfactory epithelium.  
 
                   The surface area of nasal cavity is increased by three projecting shelves of 
bone, the superior, middle and inferior turbinates located on the lateral wall of nose. 
There is a potential space under these turbinates or concha called meatus and it is 
labelled as superior, middle and inferior respectively corresponding to their respective 
turbinates. Of the three meatus middle meatus plays an important role as all of the 
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sinuses present in the nasal cavity opens into it except for the sphenoidal and posterior 
ethmoid cells which open into the superior meatus. The middle meatus with the 
sinuses opening into it forms the osteo-meatal complex which is an important area in 
the nose. Any mechanical interference in this area will affect the mucociliary 
clearance and ventilation of the sinuses. Patients who are intubated nasotracheally , 
receiving prolonged ventilation may end up with inflammation of sinuses resulting in 
chronic sinusitis if this issue is not addressed properly . Inferior meatus which is 
located just below the inferior concha receives the opening of nasolacrimal duct, the 
obstruction of which causes chronic dacrocystitis .  
 
                                       Figure 1 - Lateral wall of nose 
 
 
 
 
                                  
                               
                     
 
 
8 
 
  Respiratory and olfactory epithelium constitutes the two type of 
epithelium which are present in the nose of which olfactory epithelium extends from 
the septum to superior turbinate on the superior part of nasal cavity. The epithelium is 
of nonciliated type and contains the bipolar olfactory cells, whose axons combine to 
form the olfactory bulbs which are twenty in number. Any damage to the cribriform 
plate results in shear loss of olfactory neurons ending up in loss of smell.                   
                        Coming to the second type of epithelium, the respiratory epithelium is 
of pseudostratified type occupying the rest of nasal cavity. Respiratory epithelium 
starts from the nasal cavity and continues to the rest of airway and hence any infection 
or inflammation in the nose and sinuses tends to spread on to the lower airway 
infecting trachea and bronchi too. Below the respiratory mucosa therelies the 
submucosa containing goblet cells and mucous glands.  
                        Both internal and external carotid arteries supply the nose. Opthalmic 
artery, a branch of internal carotid artery divides into anterior and posterior ethmoidal 
artery and supplies the superior part of nose. Maxillary artery, a branch of external 
carotid artery supplies the rest of nose. Epistaxis commonly occurs on the anterior 
septum where Kiesselbach’s plexus (Little’s area) is situated. Both the ophthalmic and 
facial veins drain the nose into pterygoid and pharyngeal plexus. The drainage occurs 
both intracranially and extracranially.  
                   Nerve supply to the nose consists of autonomic, special sensory and 
sensory. First and second branches of trigeminal nerve takes over the sensory 
component whereas olfactory nerve takes over the function of special sensory part and 
atlas the branches of sympathetic fibres from first five thoracic segments of spinal 
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cord, which synapses in the superior cervical ganglion and nerve fibres from 
pterygopalatine ganglion takes over the function of sympathetic and parasympathetic 
respectively carrying out the functions of secretomotor and vasomotor control. The 
postganglionic sympathetic fibres from the superior cervical ganglion runs along with 
blood vessel to nose and hence there is vasoconstriction and decreased secretion as 
sympathetic tone increases whereas the parasympathetic fibres arise from 
pterygopalatine ganglion for which fibres comes from lacrimal nucleus of midbrain 
via nervus intermedius. Parasympathetic fibres increases secretion from the nasal 
mucosa and causes swelling of nasal mucosa. 
                            One of the prime function of nose is that it is an organ of smell but 
the most significant function is that of warming and humidification of inspired gas by 
means of its large surface area provided by concha and rich vascularity, ensuring that 
warm, clean and humidified air reaches the lungs. Nose filters gases and particles over 
4 mm and clears it with the help of mucus whereas smaller particles, which are not 
filtered by nose reaches the lung and are cleared by macrophages. Humidification of 
air is to such an extent that it is 85 to 95 % saturated in nasopharynx itself . Hence 
bypassing these areas with an endotracheal tube ensures that cold and dry gases reach 
the lower respiratory tract resulting in diminished ciliary activity proceeding to 
microatelectasis. 
 
Oral Cavity : 
 
               Oral cavity commences from the vestibule continuing on to upper and lower 
dentition, hard palate, tongue, floor of the mouth and opening of salivary glands. 
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                                                       Figure 2 - Oral cavity 
 
 
 
 
 
   
           Between the lips/cheek and gums/teeth lies the horseshoe shaped 
structure called vestibule which harbours the opening of parotid gland into it. The 
alveolar arches holding the teeth lies on the anterior part of oral cavity. Extending 
beyond the alveolar arches in the roof of nose lies the hard and soft palate. Hard 
palate, a bony plate is covered by two types of epithelium pseudostratified squamous 
epithelium above and stratified squamous epithelium below. In contrast to the hard 
palate soft palate is a muscular structure located posterior to the hard palate which on 
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elevation seperates the oropharynx from nasopharynx. The floor of oral cavity 
harbours the tongue muscles, salivary gland and its ducts between the anterior pillar of 
fauces and posterior pilar of fauces lies the tonsillar fossa on which tonsils are located. 
Anterior pillar of fauces is the start of pharynx whereas the posterior part of tongue 
continues as epiglottis. Vallecula, a depression is present between these two areas. 
Nasopharynx harbours the adenoids (Pharygeal tonsils) whereas oral cavity along with 
oropharynx contains the lingual and palatine tonsils respectively forming a complete 
ring of lymphoid tissue known as the waldeyer’s ring. (Pharyngeal, palatine and 
lingualtonsil) 
 
Pharynx : 
 
                       Oropharynx, nasopharynx and laryngopharynx are the three functional 
and topographic divisons of pharynx. Internal nares and the nasal septums’s posterior 
border forms the anterior limit of pharynx. Anterior arch of atlas and axis together 
with the basilar part of occipital bone forms the posterior wall and roof respectively 
whereas the pharynotympanic tube, communicating with the middle ear cavity and 
soft palate forms the lateral wall and floor respectively. The soft palate on contraction 
rises and seals of the oropharynx from the nasopharynx.  
                     The oropharyngeal borders are formed superiorly, anteriorly, inferiorly 
and by softpalate, tonsillar pillars and dorsal part of tongue along with superior border 
of epiglottis respectively. Posterior border is formed by Superior and middle 
constrictors respectively.  
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                    Moving on to the laryngopharynx , its extension starts from the superior 
border of epiglottis and ends upto the lower border of cricoid cartilage . Middle 
constrictor, inferior constrictor, stylopharyngeus and palatopharyngeus occupies the 
posterior wall which extends from lower border of second cervical vertebra to upper 
border of sixth cervical vertebra and it is below here where larynopharynx ends giving 
way to esophagus.   
                    As the laryngopharynx moves down, it opens anteriorly into the larynx, 
the boundaries of which are formed by the aryepiglottic fold above and cricoid 
cartilage along with posterior border of arytenoids below .Vocal cords of the laryngeal 
inlet protrudes into the laryngopharynx creating two hollows on both sides called as 
pyriform fossae. It is bounded by the thyroid cartilage along with thyrohyoid 
membrane laterally and aryepiglottic fold medially. Internal and inferior laryngeal 
nerve lies deep to the mucous membrane of pyriform recess.  
                    Pharyngeal airway unlike nasal or laryngeal airway which is being 
supported by cartilaginous or rigid bony structure , is covered by just soft tissue and 
smooth muscle alone all along it wall and hence it is easily collapsible in certain 
conditions like sleep where the mandible is being pushed posterior , during flexion of 
neck , on external compression over hyoid bone and lastly during inspiration as a 
result of negative  pressure being created in the lumen because of the diminished 
muscle tone especially when the patient is  paralysed or sedated as normally during 
inspiration the collapse is prevented by the tone of muscles covering pharyngeal wall 
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                          Figure 3 - oropharynx and laryngopharynx 
 
 
 
 
 
 
              The pharyngeal muscles of the airway has other important functions in 
addition to the functions listed above, They have phasic inspiratory activity 
synchronous with diaphragmatic contraction. On inspiration, a suction force is created 
by the intercostals muscles and diaphragm which has to be balanced with the tone of 
muscles supporting the upper airway by dilating it. So in case of any obstruction in the 
upper airway it increases the resistance thereby exaggerating the suction force causing 
collapse of the airway. Once the airway gets collapsed it becomes difficult to reopen 
it, as adhesion of collapsed wall too becomes an added force to open it.   
 
Larynx : 
 
                  It is the organ of phonation and it corresponds to the vertebral level of C3-
C6 protecting lower airway from aspirating contents of alimentary tract by means of 
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glottic valve. Muscles, ligaments and framework of cartilages forms the structure. 
Starting from epiglottis, the cartilages forming larynx are arytenoid, cricoid, thyroid, 
cuneiform and corniculate. Epiglottis, a part of laryngeal cartilages is a fibrous 
cartilage overhanging onto the laryngeal inlet and extending to the pharyngeal surface 
of tongue forming glossoepiglottic fold. Valleculae are the depressions present on 
either side of the tongue on its posterior aspect.  
             
                             Figure 4 - Larynx front view 
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                Coming to the laryngeal cavity it starts from epiglottis, the laryngeal inlet 
extending till cricoid cartilage. Aryepiglottic fold is a ligamentous structure extending 
from epiglottis to apex of arytenoid cartilages. Vestibular folds on the inner aspect of 
laryngeal cavity is termed as false cords.  Laryngeal cavity and larynx thus has a very 
important function in which we the anaesthesiologists interfere. Hence extreme 
caution has to be taken to prevent any injury or edema which may provoke spasm or 
per se difficulty in ventilation. 
                The precautions which has to be taken to prevent laryngeal trauma and 
edema in the preoperative period can be listed as selection of proper sized cuffed 
endotracheal tube which has to be neither too small to cause aspiration nor too big 
causing postoperative laryngitis and cough, secondly the volume of air we inject 
should be appropriate and finally prevent the patient from bucking due to inadequate 
plane of relaxation. 
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                    Figure 5 - Larynx Posterior view 
 
             
 
 
           
                    Extending from the anterolateral surface of each arytenoids to the angle 
of thyroid there are narrow bands of fibrous tissue on each side termed as false vocal 
cords. These false vocal cords are separated from true vocal cords by the laryngeal 
sinuses or ventricle. These true vocal cords are attached to the angle of thyroid 
cartilage and to arytenoids and are identified as pale white ligamentous structure. 
Between these two vocal cords is a triangle shaped structure termed glottis. 
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                                   Figure 6 - showing larynx again 
 
 
 
 
 
 
             
 
               The muscular part of larynx it is classified into intrinsic and extrinsic 
muscles. Cricothyroid, Posterior, transverse, oblique and lateral cricoarytenoids along 
with thyroarytenoid comes under the category of intrinsic muscles whereas 
sternothyroid, omohyoid, sternohyoid, mylohyoid, stylohyoid, geniohyoid, 
hyoglossus, genioglossus, digastrics and inferior constrictor muscles comes under 
extrinsic category. 
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                                           Figure 7 - Laryngoscopic view 
 
 
 
          
 
 
                  The nerve supply to larynx comes from internal and external division of 
superior laryngeal nerve along with recurrent laryngeal nerve. Epiglottis, base of 
tongue, cricothyroid joint, thyroepiglottic joint and supraglottic mucosa is supplied by 
internal division of superior laryngeal nerve whereas sensory supply to anterior 
subglottic mucosa, thyroepiglottic joint and motor supply to cricothyroid comes from 
external division of superior laryngeal nerve. Sensory innervations to subglottic 
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mucosa, muscle spindles and motor to thyroarytenoid, lateral cricoarytenoid, 
interarytenoid and posterior cricoarytenoid is supplied by recurrent laryngeal nerve.  
             Thus larynx is a very important structure maintaining the airway and 
protecting the airway from aspiration of gastric contents by functioning as a valve to 
occlude and protect the lower airway. Laryngeal inlet is the narrowest portion of entire 
airway system in the adults except for the anterior nasal passage. Cricoid cartilage is 
the only complete ring in our airway which has its own merits and demerits. The 
advantage is that it helps to prevent mendelson syndrome on application of sellick’s 
maneuvour whereas the disadvantage is that in case of any injury causing mucosal 
edema, the edema has to occur inwards resulting in airway obstruction.  
                 Hence the structures which play a major role in preventing the aspiration of 
foreign bodies and secretions are epiglottis, vocal cord and pharynx. Inspite of 
epiglottis covering the laryngeal inlet, it has not proved its worth in protecting airway 
soiling as it has paved way for the glottis to do the role . Hence the most important 
aspect in preventing the aspiration is glottis closure reflex. But prolonged, intense 
closure of this reflex (Glottic closure reflex) produces laryngospasm which is 
extremely dangerous for the patient as it prevents the air entry into the lower airways 
which inturn causes dyspnoea to the patient culminating in negative pressure 
pulmonary edema.  
            The airway related stimulus for laryngospasm can be from foreign body, 
secretions , anaesthetic agents and so on whereas laryngospasm may occur even from 
non airway related sources like stimulation of periosteum ,celiac plexus and also 
dilation of rectum and sometimes the reflex persist despite the removal of stimulus 
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causing it . Hundred percent FIO2 together with forward displacement of mandible 
and larson’s manouveur on mask application helps to attenuate this reflex to some 
extent. In case of persisting reflex it requires the use of muscle relaxants and 
deepening of the anaesthesia plane.  
.  
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PHARMACOLOGY : 
 
 
DEXMEDETOMIDINE : 
 
 
 
                     Dexmedetomidine  is  a  selective ∝2 – adrenoceptor agonist   that  
received  FDA  approval  in  1999. It is a short-acting drug when compared to 
clonidine. It is used in perioperative period for sedation , analgesia,  
premedication , general anaesthesia as an adjunct , neuraxial blockade  and  also  
for  post- operative  sedation  and  analgesia. 
Physiology of ∝2 -adrenoceptors : 
                 Central nervous system , peripheral nervous system, effector organs 
like pancreas , vascular smooth muscles, liver, eye , kidney are the places where 
alpha 2 adrenoreceptors are located and is divided into three types which are 
                 ∝2A - predominant subtypes in CNS, and is responsible for sedation, 
analgesia and sympatholytic effect. Dexmedetomidine  is  8  to  10  times  more  
selective  towards  ∝2 A receptor  than  Clonidine.  
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                 ∝2 B – found mainly in the peripheral vasculature, and is responsible 
for the short term hypertensive response. 
              ∝2C - found  in  the  CNS, which  is  responsible  for  the  anxiolytic 
effect & startle  response.  
.       
Figure 8 - Dexmedetomidine receptors 
 
 
                       All these subtypes produce cellular action by signalling through 
G-Protein, which couples to effector mechanisms. It differs depending on 
receptor sub-type and location. In case of  ∝2 A-Subtype , it acts on the calcium 
channels located in the locus ceruleus of the brainstem and vascular structures in 
an inhibitory fashion, on contrary the ∝2 B subtype excites the same effector 
mechanism . 
Mechanism of action of dexmedetomidine: 
                      Dexmedetomidine has its own uniqueness and doesn’t have same 
properties as the rest of sedatives. The site of action is on locus ceruleus, and 
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acts by binding to ∝2 A adrenoceptor and inhibits noradrenaline release which 
ultimately causes sedation and analgesia. Locus ceruleus has yet another 
component for dexmedetomidine to act which is nothing but descending 
medullospinal  noradrenergic pathway which are meant to perform nociceptive 
neurotransmission and which when stimulated it blocks the pain signal 
propogation resulting in analgesia. Dexmedetomidine also acts on ∝2 A 
adrenoceptor in the CNS  reducing sympathetic activity which eventually causes 
hypotension and bradycardia and along with it dexmedetomidine also increases 
the cardiac vagal activity providing sense of wellbeing and anxiolysis .          
                  At the level of spinal cord stimulation of ∝2 –receptors in substantia 
gelatinosa it causes inhibition of the nociceptive neurons firing and inhibition of 
substance P release. It also has analgesic effect by inhibiting NE release at the 
nerve endings. It has been suggested that the main cause of analgesia is due to 
the action on spinal cord but it also has been postulated with evidence that both 
the supraspinal and spinal action is responsible for all the above said actions  
                 ∝2 B - receptors located on blood vessels mediates vasoconstriction 
whereas those located on sympathetic terminals inhibit NE release. In other areas 
these ∝2 adrenoceptors cause contraction of vascular and other smooth muscles, 
decreases salivation,  secretion  and  bowel motility,  inhibits the release of renin, 
increases glomerularfiltration, decreases insulin release from pancreas, decreases 
intraocular pressure, decreases platelet aggregation and decreases shivering 
threshold by 2oC. 
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Pharmacokinetics : 
Absorption & Distribution : 
                     At 0.2 to 0.7 µg/kg/hr dose of dexmedetomidine, it exhibits linear 
pharmacokinetics and it can be administered upto 24 hrs via infusion. The 
distribution phase is very rapid and hence 6 minutes is its distribution half life 
whereas elimination half life is more when compared with distribution half life 
which is around 2 hours.            
                         Context sensitive half life, as it suggests varies depending on the 
duration of infusion. When the infusion is stopped after 10 minutes, the context 
sensitive half life is around 4 minutes whereas when it is stopped after 8 hours, 
the context sensitive half life increases to 250 minutes. The plasma concentration 
attains its peak level at 0.3 to 1.5ng/ml. 94 % of the administered is protein 
bound. 
                        The distribution volume is 118 L. Because of extensive first pass 
metabolism, the oral bioavailability is very poor but in case of sublingual route, 
the bioavailability is very high and hence has a role in paediatric premedication 
and sedation.   
Metabolism & Excretion : 
                    Dexmedetomidine undergoes biotransformation through direct N- 
glucuronidation and cytochrome P-450(CYP 2A6) mediated aliphatic 
hydroxylation producing metabolites which are inactive and the synthesised 
metabolites are eliminated in faeces(4%) and urine(95%) .  
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Pharmacodynamics: 
                  ∝-adrenoceptor agonists differs in their ∝2 / ∝1 selectivity. 
Dexmedetomidine is 8 times more potent than clonidine because of its high ∝2 / 
∝1   selectivity ratio, which is 1620:1.  
CVS: 
                   Dexmedetomidine has no effects on the heart directly but instead 
has an indirect action by increasing the oxygen extraction and vascular resistance 
of coronary arteries as the dose increases. The ratio of Supply/demand is 
unaltered. On dexmedetomidine administration there is a short hypertensive 
phase caused by the ∝2B subtype and later on switches to hypotensive phase 
caused by ∝2A subtype, thus it elicits a biphasic blood pressure response. 
Persons who have high vagal tone develops bradycardia and sinus arrest. 
RS: 
                   Unlike other sedatives dexmedetomidine does not depress 
respiratory system even when we increase the dose of the drug. It maintains 
sedation without any respiratory drive depression. Hence it is used for weaning 
and extubation in trauma & surgical ICU patients in whom previous attempts at 
weaning have failed because of agitation associated with hyperdynamic cardio 
pulmonary response. 
CNS: 
                     Dexmedetomidine reduces cerebral blood flow and cerebral 
metabolic requirement of oxygen. It reduces levels of circulating and brain 
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cetecholamines, thus balancing the ratio between cerebral oxygen supplies and 
demand. It reduces excitotoxicity, improves the perfusion in the ischemic 
penumbra, hence it has an excellent neuroprotective action. In case of 
subarachnoid hemorrhage dexmedetomidine decreases glutamate level which is 
a key agent responsible for cellular brain injury.  
Endocrine and renal effects : 
                       Dexmedetomidine activates peripheral presynaptic ∝2–AR, 
reducing catecholamine release and sympathetic response to surgery. 
Dexmedetomidine being an imidazole agent when given in short doses does not 
inhibit steroidogenesis. 
Adverse Effects: 
                      Sideeffects reported are hypotension, hypertension, nausea, 
vomiting, dry mouth, bradycardia, atrial fibrillation, pyrexia, chills, pleural 
effusion, atelectasis, pulmonary edema, hyperglycemia, hypocalcaemia, acidosis, 
etc. 
Clinical applications :  
Premedication : 
                   Dexmedetomidine is used as an adjuvant for premedication since this 
drug possess sedative, anxiolytic, analgesic, sympatholytic, and has stable 
hemodynamic profile. Premedication dose is 0.33 to 0.67 mg /kg IV given 15 
minutes before surgery. Oxygen consumption is decreased in intraoperative 
period and in post operative period.  
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Intra operative use: 
                    Dexmedetomidine attenuates the hemodynamic stress response 
which occurs during intubations and extubation by sympatholysis. 
Dexmedetomidine potentiates anesthesic effect of all the anesthesic agents, thus 
reducing their requirement.  
Loco regional analgesia: 
                     Highly lipophilic nature of dexmedetomidine facilitates rapid 
absorption into the cerebrospinal fluid. It binds to ∝2 – AR of spinal cord for its 
analgesic action. Sensory and motor block produced by local anesthetics is 
prolonged. It is also used in intravenous regional anesthesia (IVRA), brachial 
plexus block. It is also given through intraarticular route in arthroscopic knee 
surgeries to improve the duration of postoperative analgesia.  
Sedation in ICU: 
                   Dexmedetomidine produce cooperative sedation. It does not 
interfere with the respiratory drive hence it facilitates early weaning from 
ventilator, thus reducing ICU stay costs. Many studies have recommended their 
use for longer than 24 hrs. Their other beneficial effects are minimal respiratory 
depression analgesic sparing effects, desirable cardio vascular effects, reduced 
delirium & agitation. 
Procedural sedation :  
                  Dexmedetomidine is used for short term procedural sedation like 
transesophageal echocardiography, colonoscopy, awake carotid endarterectomy, 
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shockwave lithotripsy, elective awake fiberoptic intubation, pediatric MRI. The 
dose is 1 µg/kg with a maintainance dose of 0.2µg/kg/h. 
Controlled hypotension :                    
                      Spinal fusion surgery for idiopathic scoliosis, septoplasty and 
tympanoplasty operations and maxillofacial surgeries have been done with 
dexmedetomidine induced hypotension. 
Analgesia : 
                 Dexmedetomidine as said above reduces the transmission of 
nociceptive signals in the spinal cord by activating ∝2 receptors. It possesses 
significant opioid sparing effect. 
Cardiac surgery: 
                     Dexmedetomidine reduces the extent of myocardial ischemia 
during cardiac surgery. Its other uses are in the management of pulmonary 
hypertension in patients undergoing mitral valve replacement. 
Neurosurgery : 
                 Dexmedetomidine possess neuro protective effect. It also attenuates 
delirium and agitation, so that postoperative neurological evaluation will be 
easier. It has a role in functional neurosurgery like awake craniotomy surgeries 
and in Parkinson’s disease.for implantation of deep brain stimulators. 
Obesity: 
                     In morbidly obese patients this drug does not cause respiratory 
depression in the dose of 0.7µg /kg intra operatively.  
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Obstetrics : 
         Dexmedetomidine is also used in obstetrics due to its maternal 
hemodynamic stabilizing property. It also produces anxiolysis and stimulation of 
uterine contractions. Since it is highly lipophilic it does not cross placenta and 
hence it cause less chance of fetal bradycardia. 
Pediatrics : 
                 Recently it is used in pediatric patients for sedation during non-
invasive procedures in radiology like CT scan and MRI. 
Other uses : 
                  Used as an anti-shivering agent 
                  Used as an alternative to clonidine unresponsive patient  
                  Used in the treatment of withdrawal from benzodiazepines, opioids. 
 
 
 
 
 
 
 
 
 
 
 
30 
 
FENTANYL : 
                      Fentanyl, an analgesic comes under the class of opioids, Its action 
on the opioid receptor is said to be agonistic .It is synthesised from phenyl 
piperidine and is identified chemically as N-(1-phenethyl-4-piperidyl) 
propioanilide citrate (1:1) . Being more potent than morphine, its molecular 
weight is 528.61. Fentanyl citrate’s structure is 
 
 
                           Fentanyl is available in 2 & 10 ml ampoules as nonpyrogenic, 
colourless, preservative free solution . 50 mcg of fentanyl is present in each ml at 
a pH of 4 to 7.5 adjusted with sodium hydroxide.  
 
Mechanism of action: 
 
                        As fenanyl is a mu receptor agonist, its important for us to know 
about the pharmacology of mu receptors. The receptors are broadly classified into μ1 
and μ2 where the former plays the role of analgesia whereas the latter plays role on 
mediating physical dependence and bradycardia. Fentanyl binds to opioid receptor as 
an agonist and activates G protein system, and G proteins when activated inturn 
increases K+ movement to extracellular space by altering membrane permeability and 
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also decreases Ca++ movement into the cell, thereby hyperpolarising the membrane 
which ultimately inhibits neuronal function . 
                Fentanyl acts on the following sites like medulla, spinalcord , periaqueductal 
grey matter and spinal trigeminal nucleus . Spinoparabrachial and spinothalamic, the 
two ascending primary nociceptive pathways too are the targets for fentanyl where the 
former originates from superficial dorsal horn and feed areas of brain that are 
concerned with affect and the latter carries the nociceptive information to cortex areas 
concerned with both discrimination and affect . 
 
Figure 9 showing G protein coupled receptors, site of action for 
fentanyl 
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Pharmacokinetics :  
                  Fentanyl when absorbed to the blood stream rapidly distributes to 
heart, lungs, brain, kidneys and spleen because of its high lipophilicity followed 
which it slowly redistributes to muscle and fat. 80 to 85 % of the administered 
drug gets bound to plasma protein mainly with alpha-1-acid glycoprotein and 
some with albumin and other lipoproteins. Hence during acidosis the free 
fraction of drug increases. At steady state, the volume of distribution of the drug 
is about 4L/Kg 
                  Cytochrome P450 3A4 carries out the metabolic function in organs 
like liver, intestinal mucosa. The metabolite is norfentanyl which has been found 
to be inactive in animal studies. More than 90 percent of administered drug is 
eliminated by biotransformation by means of  hydroxylation and N-dealkylation 
into inactive metabolites. Rest of the drugs are excreted in faeces and urine. 
Faecel excretion is of not much significance to us. t1/2 (Elimination halflife) of 
the drug after administration is about 7 hours whereas the total plasma clearance 
of fentanyl is found to be 0.5-7L/Kg/hr                         
Pharmacodynamics & uses : 
                 Analgesia, anxiolysis, feeling of relaxation, euphoria, cough 
suppression, constipation, respiratory depression and miosis are all the 
pharmacological effects of opioid agonist. There is no ceiling effect for opioid 
agonist unlike agonist/antagonist and non opioid analgesics which means when 
the dose of opioid agonist increases, we can see a similar increase in analgesic 
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effect too and hence there is no maximum limit for its action but instead the 
maximum dose is limited to prevent the side effect of drugs especially 
respiratory depression. 
 
Analgesia: 
                 As said above there is no ceiling effect and so the level of analgesia 
correlate with the level of concentration of fentanyl in the blood stream. Side effects 
start to develop beyond a certain dose but on the other hand tolerance starts to develop 
and it increases the threshold dose at which toxicity develop. Thus the tolerance rate 
varies among individuals. 
Central nervous system: 
 
                 The mechanism by which analgesia occurs is not knowm. About the 
fentanyl, the thing known to us is that it acts on mu receptor but to our surprise many 
other receptors for endogenous compounds with opioid like activity has been found on 
which fentanyl acts. Hence it needs a detailed study before documenting whereas 
some of the other side effects and effects like respiratory depression, cough 
suppression are proven to occur because of the direct action on brain stem respiratory 
centers and cough centres in medulla respectively. The respiratory depression is due to 
non-responsiveness to both increased carbondioxide concentration and electrical 
stimulation. Fentanyl is also known to cause miosis or commonly referred to as 
pinpoint pupil. It occurs in case of opioid overdose but not in opioid overdose alone. 
Fentanyl or generally opioids are notorious for their nausea and vomiting which 
probably might be due to direct action on vomiting centres in medulla.                                    
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Gastrointestinal system : 
 
                            Increase in the tone of smooth muscles in antrum of the stomach and 
duodenum is being noted and is also associated with reduction in motility of small 
intestine along with propulsive contraction as a result of which there is quite a delay in 
the digestion of food particles. Coming to the large intestine, propulsion of peristaltic 
wave is decreased here too and the smooth muscle tone too are affected.                             
There is also a decrease in the secretion of digestive juices like pancreatic, biliary and 
gastric secretions. Smooth muscle spasm of sphincter of oddi and increase in serum 
amylase are the other findings 
 
Cardiovascular system : 
 
                        Like other opioids fentanyl causes allergic reactions by means of 
histamine release along with peripheral vasodilation which are being manifested as 
red eyes, flushing, sweating, pruritus, orthostatic hypotension. 
 Endocrine system: 
 
                       Opioids have their role on endocrine organs by inhibiting, stimulating 
or both inhibiting and stimulating the secretion of various hormones among the 
endocrine organs. ACTH and cortisol secretions are inhibited by opioids whereas  
secretion of insulin and glucagon are stimulated. The hormone which is both inhibited 
and stimulated is thyroid stimulating hormone(TSH) 
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Respiratory system: 
                             Dose dependant respiration depression is very common among 
patients receiving fentanyl because of its action on mu receptors however it is very 
less common in those patients who are  receiving chronic opioid therapy because they 
have developed tolerance to those drug effects .The respiratory physiology mentioned 
here is because of the suppression of opioid receptor present in the brainsem 
respiratory centre to any of the normal stimulus like increased CO2 concentration or 
any electrical stimulation .                      
                         Fentanyl, especially when administered swiftly causes classic muscle 
rigidity and chestwall tightness interfering with the normal respiration, causing 
dyspnoea and absent or decreased chestwall movements .Fentanyl also has antitussive 
action causing cough suppression by its direct action on cough centres located in 
medulla.  
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MIDAZOLAM : 
                 Midazolam  hydrochloride is yellow to white crystalline compound 
used in anaesthesia as a sedative hypnotic to relieve the anxiety of the patient. Being 
insoluble in water, it can be solubilised in aqueous solution by means of conversion to 
its hydrochloride salt which occurs when exposed to acidic environment. The 
chemical formula for midazolam is 8-chloro-6-(2-fluorophenyl)-1-methyl-4 H -
imidazo[1,5-a][1,4] benzodiazepine hydrochloride .The molecular formula for 
midazolam hydrochloride is C18H13ClFN3•HCl, whereas its  molecular weight is 
362.25. The structure of midazolam hydrochloride is 
 
 
          
                         Midazolam is available in vial form mixed with anhydrous sodium 
citrate,   artificial bitterness modifier, disodium edentate, mixed fruit flavour, glycerin, 
sodium benzoate, water and sorbitol. The solution is prepared in the pH between 2.8 
to 3.6 along with hydrochloric acid.  Each ml of the solutions contains either 2 or 1 
mg of midazolam hydrochloride mixed with above said components. Midazolam is 
soluble in the syrup only under acidic conditions. Midazolam plays a dual role by 
being present in two forms in an equilibrium mixture  , the open ring(Soluble in water) 
and closed ring forms(Waterinsoluble and lipid soluble) , where the former occur as a 
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result of acid catalyzed  ring opening of diazepine ring at the 4,5 double bond  and the 
later just exist perse. The percentage of open ring and closed ring form differs 
depending on the pH of the solution  which means when present in vial the percentage 
of open ring (water soluble) form is high whereas when the solution on administration 
at the physiologic pH(6 to 8) revert back to closed ring (water insoluble and lipid 
soluble) form . 
Figure 10 showing the open ring form 
 
 
             
                     The percentage of open-ring form as a function of pH in an 
aqueous solution can be plotted on a graph. The percentage of midazolam 
occurring in open ring form in aqueous solution, sensitive to pH changes only in 
the pH between 2.8 to 3.6. At a pH above 5, the existence of open ring form is 
nil or almost less than 1 percentage.                    
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Mechanism of action : 
                          Similar to other benzodiazepines, the site of action is on the GABA-
A receptors which is part of benzodiazepine-GABA receptor-Chloride ionophore 
complex. Membrane hyperpolarisation occurs as a result of opening of chloride 
channels which inhibits neuronal conduction. Also these group of drugs prevents the 
GABA reuptake thereby increasing GABA at the receptor level. This increase in 
GABA facilitates GABA mimetic action. Finally the means of amnesia occurance is 
not yet found accurately and it doesn’t correlate with the drowsiness that midazolam 
produces.       
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Figure 11 showing the GABA A receptor, site of action for    
benzodiazepines 
 
 
 
Pharmacokinetics : 
 
Distribution: 
                       
              Midazolam has high plasma protein binding capacity especially in paediatric 
patient more than one year and adult patient, almost 97% of the administered drug 
gets bound to the plasma protein, mostly albumin. α-hydroxymidazolam, a metabolite 
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of midazolam binds to plasma protein by a percentage of 89% . The mean volume of 
administration at steady state is from 1.24 to 2.02 L/Kg in paediatric patients (<16 
years to 6 months).                
Metabolism & Elimination : 
     
        Metabolism occurs at liver and intestine by human cytochrome P450 IIIA4 
(CYP3A4) producing a pharmacologically active metabolite, α-hydroxymidazolam 
which is almost equipotent as midazolam perse.  This metabolite then undergoes 
glucuronidation forming   α- hydroxymidazolam glucuronide. The glucuronidated 
metabolite, being water soluble is excreted in urine. It is being estimated that after 
intravenous or oral administration, almost 70 percent of the drug is excreted in urine. 
The other two metabolites which are of not much significance are 4-hydroxy 
midazolam (3% of administered drug) and 1,4-dihydroxy midazolam (Less than 1%).  
Both these metabolites are excreted in urine as well after conjugation with 
glucuronide. Thus no parent drug which hasn’t been metabolised or metabolite which 
hasn’t undergone glucuronidation or sulfatase deconjugation are excreted in urine 
perse.           
Uses : 
• Preoperative sedation and anxiolysis as premedicant 
• Procedural sedation for diagnostic and therapeutic procedures 
• General anaesthesia induction 
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• As maintanence drug for minor surgical procedures along with 
other anaesthetics     
• It is used as sedation in patient with ETT tube insitu on mechanical 
ventilation in critical care setting and postoperative ward for 
patients who doesn’t tolerate the artificial respiration with 
ventilator  
• It is widely used for treatment as first line of management in 
epileptic seizures.and in case of refractory status epilepticus. where 
midazolam causes burst suppression. 
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FIBEROPTIC BRONCHOSCOPE : 
                       Airway problems plays a major part in terms of morbidity and mortality 
due to anaesthesia. The available data suggests that failure to intubate and failure to 
ventilate constitutes one third of all anaesthetic deaths, for which many airway devices 
were introduced in the recent times .Fiberoptic bronchoscope is one among them. The 
flexible fiberoptic is useful to the extent that it can manage almost any difficult airway 
in the hands of a welltrained practitioner. The use of fiberoptic instruments to help in 
airway management is a relatively a recent event.  
                        Fiberoptic instrument was first used by Dr.Murphy in 1967 for a nasal 
intubation.  He performed the procedure in a patient with advanced still’s disease 
under General anaesthesia with a choledocoscope 
 
Fiberoptic scope basics : 
 
              Light travels in different velocity in different substance .Velocity of light 
through the substance with that through vacumm indicates the refractive index of the 
substance , based on which the velocity of light differs for each substance . Hence 
there is alteration in the direction of light beam as it  travels from one substance to the 
other .This difference in velocities has the effect of  altering the direction of a light 
beam as it passes from one medium to another.  Light passes straight through when it 
hits a glass-air interface at 90 degree, other than that degree light seems to alter its 
direction. Hence the angle of incidence plays a major part, which tells why a light 
 
 
43 
 
bends better when its angle of incidence is increased from the perpendicular as it 
travels from glass to air .  
Figure 12 : Showing fiberoptic scope cut section 
 
                      
 
                               
 
             Finally at a point there will be total internal reflection of light where the  
light is  reflected back inside the glass , the angle of incidence at which this occurs is 
said to be the critical angle . So its possible for a light to travel from one end of a glass 
rod to the other  
Design : 
 
              The fiberoptic scope, being flexible can transmit image from the distal tip to 
proximal end. The tip of fiberoptic scope is designed in a fashion that its motion can 
be controlled in any direction which provides an opportunity for the operator to direct 
the scope in any direction and hence 
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• Controllability 
 
• Flexibility 
 
• Image transmission  
 
are said to be the hallmark features of fibreoptic scope .  
 
                                     The proximal and distal end of the scope are tightly fastened 
together by organised, coherent bundle of flexible fibres which are optically insulated. 
Its these features which helps in image transmission. Also each fibres are coated with 
a transparent substance of lower refractive index called cladding which helps in light 
transmission and optical insulation of fibers. 
                  
                       Figure 13 showing the parts of fiberoptic scope 
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Manipulation and handling the scope : 
 
                   Nasal or oral route can be chosen for intubation in fiberoptic scope  
 
depending on the user’s ease. Maneuvers to handle the scope are listed below              
 
• Moving in and out controls the depth 
 
• Rotation of the scope controls the anterior/posterior motion 
 
• Tip manipulation for side movement 
 
The insertion cord should be free of torque in order to maintain the  
control of tip of fibreoptic scope .The control unit should be held in one hand and the 
insertion cord to be stretched in a taut manner for a better view . Insertion cord if 
twisted results in loss of coordinated motion between control lever in the handle and 
the tip of fiberoptic scope.  
                      Figure 14 showing parts of fiberoptic cord 
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MATERIALS AND METHODS : 
 
 
• Study Design and setting  
• Sample size calculation 
• Study population  
• Randomization and Allocation 
• Masking 
• Objective 
• Anaesthesia protocol 
• Premedication  
• Pre-induction period 
• Induction and maintenance 
• Protocol  
• Results 
• Statistical analysis 
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METHODS : 
 
Study design: 
 
  This was a single centre, prospective, randomized, parallel group, double 
blinded study. The study was conducted in the department of Anaesthesiology, 
Tirunelveli Medical College, Tirunelveli from the period March 2014 to December 
2014. 
  After institutional ethical committee approval and written informed consent, 
40 adult patients of both sexes, within the age group of 25 to 50 years belonging to 
ASA 1 & 2 physical health status undergoing thyroid surgery were recruited. They 
were randomized using computer generated random numbers and allocated into two 
groups, Group D and Group FM as follows 
Group D:  Received 1 mcg/kg of  Dexmedetomidine administered over 10 mins 
 followed by infusion dose of 0.7 mcg/kg/hr. 
Group FM: 2 mcg/kg of Fentanyl with 40 mcg/kg of midazolam over 10 mins  
followed by an infusion of normal saline.  
Sample size calculation:  
             Sample size was chosen to be 40 and was calculated from 
1. Correlation coefficient 
2. Alpha error which we kept as 20 % 
3. Power of the study which in turn was calculated from beta error which was 
assumed to be 5 % (Power of the study = 1 – beta error) 
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Study population : 
Inclusion criteria  
  
 Age : > 25years < 50 yrs.  
  ASA (American Society of Anaesthesiologists) 1& 2 patients  
 BMI: 20 – 30 
 Patients undergoing thyroid surgery with euthyroid status 
             Exclusion criteria  
• Patient  refusal 
• Emergency surgeries 
• Difficult airway 
• Coagulopathies or any bleeding disorder 
• Fracture base of skull 
• Ischemic heart disease/Valvular heart disease/arrrythmia or any conduction 
abnormalities 
• Known hypersensitivity to any of the study drugs 
• Raised intracranial pressure 
• Uncontrolled seizure disorder   
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• Known psychiatric illness, receiving treatment in the past two weeks, where 
either dexmedetomidine or benzodiazepine administration is  contra-indicated 
• Heart rate <50bpm & Systolic blood pressure <90 mmHg  
• Patients with respiratory system disorders , renal disorders & liver disorder  
MASKING: 
                  The study was carried out in a double blinded fashion. The patients on 
whom study was conducted were blinded and they did not know what drug they were 
administered. The drugs, both for bolus administration and infusion was prepared by 
an anaesthesiologist who was not involved in the study and hence the investigator who 
conducted the study was also blinded.  
                    Both the group received 50 ml of bolus dose administered over 10  
minutes at a rate of 5 ml/min,  with group D receiving dose of 1 mcg/kg  
dexmedetomidine and group FM  2 mcg/kg of fentanyl and 40 mcg/kg of midazolam 
.Patients in both the group were followed with infusion of 100 ml plain normal saline 
in case of Group FM and 100 ml of normal saline  mixed with dexmedetomidine at the 
rate of 0.7 mcg/kg/hr for dexmedetomidine .      
PROCEDURE : 
                After pre-anaesthetic evaluation, the more patent nostril (right or left 
sided) was identified.Inj. Glycopyrrolate 0.2 mg intramuscularly was given as 
premedicant 45 mins before the procedure. Nasal and oral part of airway was 
anaesthetised by means of nasal packing and oral gargling with 4 % Lignocaine, 15 
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mins before the start of procedure. Nasal packing was done with 4 cotton pledgets 
soaked in 4 ml of 4 % Lignocaine mixed with adrenaline (1:200000 dilution) two each 
for both the nostrils. Oral gargling was performed with 2 ml of 4 % lignocaine. iv 
infusion of ringer lactate started in the nondominant arm after securing intravenous 
access . ECG, NIBP, SpO2 monitors were connected to the patient, and ETCO2 after 
intubation. Anaesthetist who is experienced and well trained with fibreoptic scope and 
a skilled the are technician was called for and made ready in case if any help is 
needed. Fiberoptic scope, light source and appropriate sized endotracheal tubes were 
kept ready. All the components of boyle’s checklist were verified and ensured that 
nothing is missed before administering the drug.  
                         Baseline heart rate , BP , SpO2  were recorded and noted down after 
which the bolus drug , Dexmedetomidine or Fentanyl & midazolam based on the 
group was administered over 10 minutes followed by infusion . Sedation level was 
graded as 1, 2, 3 & 4. Intubation commenced when sedation level reached grade 2. 
Local anaesthetic was sprayed as the fibreoptic scope went past the oropharynx, after 
the glottis was visualized. Time taken for intubation, ease of intubation and comfort 
scores of the patient were noted down. Hemodynamic variables like heart rate, Spo2, 
systolic BP, Diastolic BP, Mean arterial pressure & respiratory rate were noted at the 
end of intubation, 6 th, 8 th & 10 th minute after the procedure. After which patients 
were observed for the following secondary outcomes  
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• Hemodynamic variables 
 
• Sedation scale based on Ramsay sedation scoring system 
 
• Ease of intubation based on intubation scoring system 
 
• Comfort scores modified from Ambu et al 
 
• Intubation time 
 
• Airway trauma 
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SEDATION: 
Assessed as six point scale (Ramsay sedation scale) 
GRADE DESCRIPTION 
1 Anxious and agitated or restless, or both 
2 Co-operative, oriented, and tranquil 
3 Responds to commands only 
4 Exhibits brisk response to light glabellar tap or loud auditory stimulus 
5 Exhibits a sluggish response to light glabellar tap or loud auditory 
stimulus 
6 Exhibits no response 
 
INTUBATION SCORES: 
Assessed by vocal cord movement 
GRADE VOCAL CORD MOVEMENT 
0 Open 
1 Moving 
2 Closing 
3 Closed 
 
 
 
 
 
 
 
53 
 
COMFORT SCALES: 
 
 ALERT
NESS 
CALM
NESS 
RESPIRA
TORY 
RESPONS
E 
CRYI
NG 
PHYSIC
AL 
MOVE
MENT 
MUSC
LE 
TONE 
FACIAL 
TENSION 
1 Deeply 
asleep 
Calm No 
coughing 
and no 
spontaneou
s 
respiration 
Quiet 
breathi
ng, no 
crying 
No 
movemen
t 
 
Muscle
s 
totally 
relaxed
, no 
muscle 
tone 
Facial muscle 
totally relaxed 
2 Lightly 
asleep 
Slightly 
anxious  
Spontaneou
s 
respiration 
Sobbin
g or 
gasping 
Frequent 
slight 
movemen
ts 
Reduce
d 
muscle 
tone 
Facial muscle 
tone normal, no 
facial 
muscle tension 
evident 
3 Drowsy Anxious Occasional 
cough 
Moanin
g 
Vigorous 
movemen
t limited 
to the 
Extremiti
es 
Normal 
muscle 
tone 
 
Tension evident 
in some facial 
muscles 
4 Fully 
awake & 
alert 
Very 
anxious 
Coughing 
regularly 
Crying 
 
Vigorous 
movemen
ts 
including 
torso 
and head 
Increas
ed 
muscle 
tone 
and 
flexing 
of 
fingers 
and 
toes 
 
Tension evident 
throughout facial 
muscles 
 
5 Hyper-
alert 
Panicky Frequent 
coughing or 
choking 
Scream
ing 
Occasion
al slight 
movemen
t 
Extrem
e 
muscle 
rigidity   
Facial muscles 
contorted and 
grimacing 
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                    The total comfort score for each patient was calculated by adding the 
scores of the 7 comfort categories at each time point(Modified from ambu et al). 
Patients score is calculated from a total Score of 35. 
                    The information collected from all cases were recorded in a master sheet. 
Mean and Standard Deviation, Median and Percentiles were provided for all the 
continuous variables and frequencies and percentages for categorical variables. The 
outcome variables were compared between pre and post measurements using Paired t-
test, if they are normally distributed. For variables which were not normally 
distributed Wilcoxon Signed Rank Test was used to compare the medians between pre 
post measurements. 
        Data was analyzed using Statistical package for social science (SPSS) 
software and Sigma Stat 3.5 version (2012). Using this software, frequencies, 
percentage, mean, standard deviation and ‘p’ value were calculated through  
• Student ‘t’ test 
• One way ANOVA 
• Chi square test   
P value of < 0.05 was taken as significant. 
 
 
 
 
 
 
 
55 
 
RESULTS                                    
 Table 1 : Showing the mean , standard deviation , P & T value regarding 
to age 
Group Mean SD P value T value 
Fent&Midaz 36.6 13.03 0.513 0.66 
Dexmed 39.2 11.85 
 
Fig 15 : Comparison of  age distribution between the two groups 
distribution 
                      
    
 
                       The age incidence of our study belonged to patients of all ages  
 in the range of 25 to 50 years as shown in table 1 with mean falling in the mid  
range 
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Figure 16 : Comparison of  sex distribution between the two groups 
 
 
 
           The male and female populations of our study was distributed equally with ten 
in each group and in each category . 
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Table 2 – Comparison  of  weight distribution between two groups 
     Group Mean SD P value T value 
Fent&Midaz 62.45 13.14 0.783 0.278 
Dexmed 63.75 16.28 
 
 
Figure 17 : Comparison of  weight distribution among the two groups 
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Table 3 – Comparison of  BMI distribution between  two groups 
     Group Mean SD P value T value 
Fent,Midaz 22.46 4.38 0.587 0.548 
Dexmed 23.28 5.05 
 
 
 
Figure 18 : Comparison of  mean distribution of BMI between  two groups 
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Table - 4  Comparison of  height distribution between two groups 
     Group Mean SD P value T value 
 Fent,Midaz 165.5 5.79 0.672 0.426 
 Dexmed 164.65 6.77 
 Total         
 
Figure 19 : Comparing the mean distribution of height among two groups 
 
                              
                 The difference in height, weight, BMI of the study population between the 
two study groups were comparable but not statistically significant 
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Figure 20 : Comparing the distribution of population based on their  
Mallampatti airway class  
 
 
                       Fifty percent of the population in our study group belong to  
Mallampatti class 1, above 40 percent to class 2 and remaining to class 3.                                
None of our study population belonged to Malllampatti class four airway. 
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Figure 21 : Comparing the distribution of population based on thyromental  
distance 
 
 
                  
 
  Over 90 percentage of our population had TMD > 6.5 
 
 
 
 
0
2
4
6
8
10
12
14
16
18
20
<6.5 >6.5
1
19
2
18
PO
PU
L
AT
IO
N
 N
U
M
B
E
R
THYROMENTAL DISTANCE
TM DISTANCE
FENT,MIDAZ DEXMED
 
 
62 
 
Figure 22 : Comparing the incidence of airway injury between the two  
groups
                           
Ninety five percent and ninety percent of the population did not have  
airway trauma in group D and group FM respectively . 
Statistical significance existed between two groups in terms of 
• Intubation time in seconds 
• Sedation scale 
• Comfort score 
• Hemodynamic variables 
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Table  5 – Comparison of  sedation scale  between two groups 
 GROUP Mean SD P value T value 
Fent&Midaz 1.55 0.76 0.005 2.97 
Dexmed 2.15 0.49 
 
Figure 23 : Comparing  the sedation scale achieved between the two groups 
 
 
 
                  Dexmedetomidine group had a better sedation score when  
compared with fentanyl midazolam group. The sedation score was adequate providing  
the patient with anxiolysis and a good conscious sedation  with amnesia as well. 
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Table 6 – Comparison of Intubation time between two groups 
GROUP Mean SD P value T value 
Fent&Midaz 20.87 4.27  <0.001  4.45 
Dexmed 15.92 2.56 
 
Figure 24 : Showing the comparison of Intubation time between two groups  
  
           Except for 3 patients, the intubation time was less in dexmedetomidine group 
whencompared with fentanyl-midaz group with statistical significance (P value 
being<0.001) 
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Table 7 – Showing the comparison of comfort score between two groups 
 GROUP Mean SD P value T value 
Fent&Midaz 15.95 1.73  <0.001 9.82 
Dexmed 11.3 1.22 
 
Figure 25 : Comparing comfort score level between two groups achieved by  
each  patient 
 
Dexmedetomidine group patients were better comfortable with  
the procedure than fentanyl midazolam group . Comfort score was calculated  
out of 35 based on 7 entities . Dexmed group had a mean value of 11.3 when  
compared with fentanyl midazolam group which had a mean value  of 15.95 
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(lower the comfort score ,  better the patient was) 
             
                       In case of hemodynamic variables again dexmedetomidine group 
patients had a better hemodynamic scores than fentanyl midazolam group patients.                        
 
Table 8 – Comparison of pulse rate scores between two groups 
                     
        
TIME 
FENT&MIDAZ DEXMED     
Mean SD Mean SD P value T 
value 
Base line 84.6 8.78 82.95 11.66 0.616 0.505 
Before Intubation 
83.5 6.76 81 7.64 0.28 1.09 
After intubation 
115.4 9.03 101.9 9.39  <0.001 4.63 
6th min 103.9 11.36 94.25 9.65 0.006 2.89 
8th min 95.55 8.13 89.55 7.84 0.023 2.37 
10th min 85.2 10.47 82.4 7.79 0.343 0.96 
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Fig 26 : Line graph showing pulse rate variations among two groups 
 
                                     
                                  PULSE RATE DISTRIBUTION 
 
 
 
                         After intubaion , 6 th and 8 th minute pulse rate scores were  
statistically significant  with  P value being <0.001 , 0.006 , 0.023 respectively              
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Table 9 – Comparison of  systolic BP scores between two groups 
 
 
TIME  FENT,MIDAZ DEXMED     
Mean SD Mean SD P value T 
value 
Base line 125.8 16.72 126.05 13.97 0.959 0.051 
Before Intubation 
119.75 15.01 124.35 14.05 0.323 1.001 
After intubation 
149.25 12.47 140.95 15.01 0.065 1.902 
6th min 142.6 14.73 133.75 12.37 0.047 2.06 
8th min 131.4 17.03 129.9 9.86 0.744 0.329 
10th min 
122.75 20.79 126 13.33 0.562 0.586 
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Fig 27 : Comparing systolic BP variations between two groups 
 
SYSTOLIC BP DISTRIBUTION 
 
 
 
After intubation and 6 th minute scores were statistically significant 
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Table 10 – Comparison of  diastolic BP scores between the two groups 
 
TIME  FENT,MIDAZ DEXMED     
Mean SD Mean SD P value T value 
Base line 81.9 13.56 78.3 10.33 0.351 0.945 
Before Intubation 76.9 11.25 77.35 12.99 0.907 0.117 
After intubation 93.55 13.97 85.8 9.6 0.037 2.16 
6th min 89.3 13.45 80.8 11.15 0.036 2.17 
8th min 85.6 12.83 79.75 9.78 0.113 1.62 
10th min 79 15.54 75.65 10.06 0.424 0.809 
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Fig 28 : Comparing diastolic BP variations between the 2 groups 
 
 
DIASTOLIC BP DISTRIBUTION 
 
                                
          
                           After intubation & 6 th minute scores were statistically significant  
with  P  value being 0.037 & 0.036 respectively.  
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Table 11 - Comparing  MAP(mean arterial pressure) between the two  
groups 
 
TIME  FENT,MIDAZ DEXMED     
Mean SD Mean SD P value T value 
Base line 96.5 15.02 92.3 21.84 0.483 0.709 
Before Intubation 91.3 11.92 95.4 14.01 0.325 0.997 
After intubation 116.55 14.45 105.5 12.5 0.014 2.58 
6th min 109.6 15.86 99.2 11.5 0.023 2.37 
8th min 101.4 15.56 97.9 9.09 0.39 0.869 
10th min 93.65 18.37 93.6 10.04 0.992 0.011 
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Fig 29 : Comparing MAP variations between two groups 
 
                                    
          
                After intubation & 6 th minute values were significant with P value being  
0.014 & 0.023 respectively .   
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Table 12 Comparison of Spo2 scores between the two groups 
 
 
TIME  
FENT MIDAZ DEXMED     
Mean SD Mean SD P value T 
value 
Base line 100   100   1   
Before Intubation 100   100   1   
After intubation 97.5 2.67 99.2 1.74 0.022 2.38 
6th min 99.4 0.41 99.85 0.49 0.003 3.15 
8th min 100   100   1   
10th min 100   100   1   
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Fig 30: Showing SpO2 variations between two groups 
 
                                    SPO2 DISTRIBUTION 
 
         
  After intubation & 6 th minute were statistically significant with P value being 
0.022 & 0.003 respectively . 
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DISCUSSION 
                          Awake fibreoptic intubation, one of the modalities in difficult airway 
management is an unpleasant procedure which definitely needs an ideal sedative 
regimen satisfying patient in all aspects by providing adequate analgesia, amnesia, 
anxiolysis, anti-sialogogue, better respiratory and  hemodynamic parameters .  
                           Fentanyl midazolam combination may provide adequate 
analgesia,amnesia,anxiolysis but is known to  produce apnea and hypoxemia even in 
healthy volunteers .  But dexmedetomidine, a recently introduced drug, an alpha 2 
adrenoreceptor aganist seems to be satisfying   all the patient needs in all aspects.  
                          In view of existing controversies and lack of consensus in previous  
literatures , this study was carried out  over a one year  period  with the principal aim  
of  comparing  dexmedetomidine alone with fentanyl- midazolam combination as an 
ideal agent for providing  sedation for AFOI.  
                           In this study we have shown that Dexmedetomidine convincingly is a 
superior & better drug in terms of providing sedation for awake fibreoptic intubation 
in all aspects. The plane of sedation provided by this drug was excellent such that it 
neither produced a deep sedation making the patient well asleep depressing his 
respiration nor a superficial plane where the patient is anxious and agitated. It was an 
intermediate plane where the patient is conscious, responding to commands, calm with 
a better hemodynamics and respiratory parameter.  
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                         Quoting others literature, Bergese et al in his study has shown that 
Patients belonging to dexmedetomidine group were more satisfied and comfortable 
than the midazolam group. 
                         Further in our study dexmedetomidine group patient had better 
comfort score when compared with fentanyl midazolam group. Comfort score was 
calculated based on 7 parameters, which were calmness, alertness, crying, physical 
movement, respiratory response, Facial tension and muscle tone. The lower the score, 
the better the patient was.  
                       Also the patients belonging to dexmedetomidine group had less airway 
trauma when compared with fentanyl midazolam indicating group D patients were 
better prepared for the procedure. 
                      Intubation time in dexmedetomidine group patients was faster when 
compared with fentanyl midazolam group which tells that Group D patients were 
easier to intubate as they were more cooperative and calm. 
                      Dexmedetomidine group patients also had better hemodynamics when 
compared with fentanyl midazolam group.  
                   Further Dexmedetomidine group had better respiratory parameters in 
terms of SpO2. Midazolam especially in combination with fentanyl is known for 
its respiratory depression and decrease in SpO2 whereas dexmedetomidine group 
has respiratory sparing effect even in high doses. Bailey et al too had quoted in 
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his literature that fentanyl midazolam combination produces respiratory 
depression and hypoxia.  
                   Kamibyashi et al has quoted that dexmedetomidine has additional 
antisialogogue effect making intubation easier and intubation time shorter. 
 
Table 13 : Comparison of  similar studies 
STUDY INFERENCE 
Bailey et al 
 
Fentanyl and midazolam use has produced significant 
hypoxia and apnea even in healthy adult volunteers. 
Bergese et al 
 
Dexmedetomidine group patients were more calmer , 
cooperative and satisfied when compared with others. 
 
Tsai et al 
 
Respiratory depression is lesser with dexmedetomidine  
group when compared with propofol group. 
 
Avitsian et al Dexmedetomidine had better intubating conditions in 
patients with cervical spine injury. 
Chu et al  
 
In oral cancers for whom intubation was difficult , 
dexmedetomidine was very much efficacious. 
Bloor et al 
 
Dexmedetomidine has a biphasic blood pressure response, 
initial hypertension due to vasoconstriction of peripheral 
vessels. 
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LIMITATIONS 
 Our study was limited by small sample size.       
           The choice of route for intubation was decided to be nasotracheal, had it  
been orotracheal it would have been more comfortable for the patients and the  
parameters like comfort scores and hemodynamic variables would have been  
better.   
CONCLUSION  
             We conclude that dexmedetomidine is a safe and highly  efficacious  
drug in providing sedation , amnesia ,  anxiolysis , analgesia , better  
hemodynamics without  producing  respiratory depression for awake fibreoptic   
intubation..  
                  We also conclude that ease of intubation, cough suppression, 
comfort  score & sedation scale was better with  Dexmedetomidine . 
 
 
 
 
 
 
 
 
 
 
 
80 
 
REFERENCES : 
 
1) Bhana N, Goa KL, McClellan KJ. Dexmedetomidine Drugs. 2000 
 
 Feb;59(2):263-8 
 
2) Martin E, Ramsay G, Mantz J. The role of the alpha2-adrenoceptor  
 
Agonist  dexmedetomidine in postsurgical sedation in the intensive care  
 
unit. Journal of Intensive Care Med. 2003 Jan-Feb;18(1):29 
 
 3) Kamibayashi T and Maze M. Clinical uses of alpha -2 adrenergic agonists. 
 
     Anesthesiology 2000;93:1345-9. 
 
4) Boyd BC and Sutter SJ. Dexmedetomidine sedation for awake fiberoptic  
 
Intubation of patients with difficult airways due to severe odontogenic  
 
cervicofacial infections. J Oral Maxillofac Surg. 2011 Jun;69(6):1608-12.  
 
doi: 10.1016/j.joms.2010.11.004. Epub 2011 Mar 9. 
 
5) Grant SA, Breslin DS, MacLeod DB. Dexmedetomidine infusion for  
 
Sedation during fiberoptic intubation: A report of three cases. Journal of  
 
Clinical Anaesthesia 2004 16: 124 
 
 6) Bergese SD, Bebder SP, Mc Sweeney BS. A comparative study of 
 
     dexmedetomidine with midazolam and midazolam alone for sedation during  
 
     elective awake fiberoptic intubation. Journal of Clinical Anaesthesia 2010:  
 
     22: 35-40. 
 
 7)Avitsan R, Lin J, Lotto M. Dexmedetomidine and awake fiberoptic  
 
intubation for possible cervical spine myelopathy. J Neurosurg  
 
Anaesthesiology  2005; 17: 97- 
 
 
81 
 
 
 8) Bergese SD, Khabiri B, Roberts WD, Howie MB, McSweeney TD, Gerhardt 
 
    MA. Dexmedetomidine for conscious sedation in difficult awake fiberoptic 
  
     intubation cases. J Clin Anesth 2007; 19:141–4. 
 
 9) Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and 
 
     analgesic properties of small-dose dexmedetomidine infusions. Anaesth          
 
     Analg 2000; 90:699–05. 
 
10) Ramsay MAE, Luterman DL. Dexmedetomidine as a total intravenous 
 
 anaesthetic agent. Anaesthesiology 2004; 101:787–90. 
 
11)Bergese SD, Khabiri B, Roberts WD, Howie MB, McSweeney TD, Gerhardt 
 
     MA. Dexmedetomidine for conscious sedation in difficult awake fiberoptic 
 
     intubation cases. J Clin Anesth 2007; 19:141–4. 
 
12) Grant SA, Breslin DS, Macleod DB, Gleason D, Martin G.  
 
      Dexmedetomidine infusion for sedation during fiberoptic intubation: a  
 
      report  of three cases. J Clin Anesth 2004; 16:124-6. 
 
13) Abdelmalak B, Makary L, Hoban J, Doyle DJ. Dexmedetomidine as sole 
 
      sedative for awake intubation in management of critical airway. J Clin  
 
      Anesth 2007; 19:370–3. 
 
 14) Neumann MM, Davio MB, Macknet MR, Applegate RL II.  
 
       Dexmedetomidine for awake fiberoptic intubation in a parturient with  
 
       spinal  muscular atrophy type III for cesarean delivery. Int J Obstet Anesth  
 
       2009; 18:403–7. 
 
 15) Madhere M, vangura D, Saidov A. Dexmedetomidine as sole agent for  
 
 
 
82 
 
       Awake fiberoptic intubation in a patient with local anesthetic allergy. J  
 
       Anesth 2011;10:1007. 
 
 16) Tsai CJ, Chu KS, Chen TI, Lu DV, Wang HM, Lu IC. A comparison of the 
 
    effectiveness of dexmedetomidine versus propofol target-controlled  
 
          infusion for sedatoin during fiberoptic nasotracheal intubation. 
 
         Anaesthesia  2010;65:254–9. 
 
  17) Kim YY. Sedation for fiberoptic awake nasotracheal intubation:   
 
         Comparison between propofol infusion and intravenous boluses of  
 
        fentanyl and midazolam. Korean J Anesthesiol 1997; 33:741–9. 
 
  18)  Nelson LE, You T, Maze M, Franks NP. Evidence that the mechanism of 
 
         hypnotic action in dexmedetomidine and muscimol-induced anesthesia  
 
        converges on the endogenous sleep pathway. Anesthesiology 2001;  
 
        95:368. 
 
 19) Rozet I. Anesthesia for functional neurosurgery: the role                                       
 
       of  dexmedetomidine. Curr Opin Anesthesiol 2008; 21:537–43. 
 
20) Venn RM, Bradshaw CJ, Spencer R, Brealey D, Caudwell E, Naughtan  
 
      C,et al. Preliminary UK experience of dexmedetomidine: a novel agent  
 
     for postoperative sedation in the intensive care unit. Anaesthesia  
 
     1999;54:1136–42. 
 
21) Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous  
 
      Dexmedetomidine in humans. Anaesthesiology 1992; 77:1134–42. 
 
22) Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of  
 
      Increasing plasma concentrations of dexmedetomidine in humans.  
 
 
83 
 
 
      Anaesthesiology 2000; 93:82–94. 
 
23)  Ebert T, Maze M. Dexmedetomidine: another arrow for the clinician’s  
 
       quiver. Anaesthesiology 2004; 101:568–70. 
                
24)  Jorden VS, Pousman RM, Sanfor MM, Thorborg PA, Hutchens MP.  
                     
       Dexmedetomidine overdose in the perioperative setting. Ann Pharmacother 
 
       2004;38:803–7. 
 
25) Avitsian R, Manlapaz M, Doyle DJ. Dexmedetomidine as a sedative for  
 
      awake fiberoptic intubation. International Trauma Care (ITACCS) 2007;  
 
      17:19–24. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
COMPARISON BETWEEN DEXMEDETOMIDINE 
AND A COMBINATION OF MIDAZOLAM AND  
FENTANYL  FOR SEDATION DURING  AWAKE 
FIBEROPTIC INTUBATION – A 
PROSPECTIVE,RANDOMIZED, PARALLEL GROUP, 
DOUBLE-BLINDED STUDY 
                                            
                                                 PROFORMA 
 
Name :                                                                      Age : 
Diagnosis :                                                               ASA status : 
 
PATIENT EVALUATION : 
 
Pulse :                                                                        BP : 
RR :                                                                           Airway : 
CVS :                                                                         RS : 
INVESTIGATIONS : 
 
Hb% :                                                                         RBS : 
BT :                                                                            CT : 
Blood Urea :                                                               Ser Creatinine : 
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Blood Grouping & typing                  : 
 
 
 
                                                                                       GROUP D 
GROUP 
                                                                                      GROUP FM 
 
SEDATION SCALE                          :                           0/1/2/3 
 
INTUBATION SCORE                      :                           0/1/2/3 
 
COMFORT SCORE                          : 
  (Out of 35) 
 
AIRWAY TRAUMA                          :                          YES / NO 
 
 
INTUBATION TIME                         : 
(In seconds) 
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                                                                 HEMODYNAMIC VARIABLES 
TIME DRUG& 
DOSE 
H/R       BP 
SYSTOLIC 
       BP 
DIASTOLIC 
   BP 
MEAN 
SpO2 RR 
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                                                                         MASTER CHART 
S.No. Age Yrs Sex 
Wt. 
Kg 
Ht.  
cm BMI ASA MPC 
TM 
Distance  
cm 
PR SYS. BP 
Base 
Line    
0 
min. 
Before 
Intubation 
2nd min. 
After 
Intubation 
4th min. 
6th 
min. 
8th 
min. 
10th 
min. 
Base 
Line    
0 
min. 
Before 
Intubation 
2nd min. 
After 
Intubation 
4th min. 
6th 
min. 
8th 
min. 
10th 
min. 
1 30 F 42 160 16.4 1 1 > 6.5 86 80 108 102 98 90 120 120 156 137 116 113 
2 42 M 65 170 22.5 1 3 > 6.5 88 80 128 17 105 90 127 121 163 149 143 136 
3 50 F 55 164 20.4 1 2 > 6.5 80 82 118 108 101 82 149 143 172 158 139 132 
4 28 M 72 170 24.9 1 1 > 6.5 76 70 98 90 86 82 145 98 150 133 129 120 
5 32 F 51 163 15.2 1 2 > 6.5 72 80 102 82 80 72 123 127 136 122 121 112 
6 35 M 76 176 24.5 1 1 > 6.5 86 90 117 101 98 86 147 123 139 147 142 134 
7 63 M 60 169 21 1 1 > 6.5 90 90 108 104 94 92 130 131 163 149 135 136 
8 20 F 40 160 15.6 1 1 > 6.5 92 86 112 110 16 92 100 106 147 142 100 96 
9 43 M 80 170 27.7 1 2 > 6.5 86 88 130 124 112 106 134 137 156 156 150 140 
10 25 M 74 172 25 1 3 > 6.5 80 90 120 122 106 112 92 90 134 132 127 91 
11 30 F 60 56 24.7 1 2 > 6.5 83 85 104 96 98 80 118 113 131 132 101 98 
12 40 F 70 160 27.3 1 2 < 6.5 84 92 114 98 94 82 131 131 199 162 141 145 
13 32 M 73 173 24.4 1 1 > 6.5 76 70 117 90 86 78 137 131 149 140 135 101 
14 65 M 52 165 19.1 1 2 > 6.5 72 74 112 92 82 74 156 143 199 164 159 156 
15 30 F 72 160 28.1 1 2 > 6.5 78 82 110 94 98 68 125 113 156 143 120 120 
16 18 F 40 156 16.4 1 1 > 6.5 90 88 120 112 100 90 113 118 131 133 118 113 
17 53 M 75 164 27.9 1 2 > 6.5 112 88 120 104 89 80 123 104 195 197 164 156 
18 36 F 69 166 25 1 2 > 6.5 90 93 114 114 90 86 129 131 156 162 141 150 
19 37 M 75 172 25.4 1 1 > 6.5 86 80 126 108 98 82 101 99 145 116 116 103 
20 23 F 48 164 17.8 1 1 > 6.5 85 82 130 120 100 80 116 116 128 118 131 103 
21 40 F 68 164 25.3 1 2 > 6.5 72 82 104 98 90 70 140 132 140 133 131 129 
22 32 M 73 170 25.3 1 1 > 6.5 78 70 98 87 80 81 122 127 145 131 120 128 
23 65 M 60 169 21 1 1 > 6.5 84 86 108 97 91 87 141 149 156 151 141 137 
24 62 F 43 150 19.1 1 1 > 6.5 86 90 112 90 94 82 98 87 101 99 113 91 
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25 28 F 42 154 17.7 1 1 > 6.5 80 87 100 9 81 74 120 113 131 118 120 116 
26 48 F 80 160 31.2 1 2 < 6.5 82 77 114 112 99 90 128 118 143 134 134 137 
27 29 M 78 172 26.4 1 2 > 6.5 76 75 90 72 74 76 120 129 141 125 129 129 
28 25 M 80 173 26.7 1 2 > 6.5 74 70 88 84 86 76 101 98 120 131 122 123 
29 43 F 60 165 22 1 1 > 6.5 82 84 100 92 88 80 135 136 154 147 142 136 
30 44 F 45 160 17.6 1 2 > 6.5 88 90 98 90 92 92 143 137 156 150 143 135 
31 29 M 73 169 25.6 1 1 > 6.5 98 80 88 83 80 70 113 118 129 120 128 118 
32 41 M 80 172 27 1 2 > 6.5 98 92 106 110 104 98 133 135 149 141 137 133 
33 32 M 81 170 28 1 3 > 6.5 9 95 110 98 97 88 131 120 135 137 125 128 
34 33 F 43 162 16.4 1 1 > 6.5 86 80 98 100 90 82 127 125 149 140 136 135 
35 25 F 49 163 18.4 1 1 > 6.5 72 72 90 92 88 78 126 127 164 143 149 131 
36 50 M 52 168 18.4 1 2 > 6.5 108 80 120 104 102 92 113 122 131 133 116 120 
37 28 F 35 154 14.8 1 1 > 6.5 96 82 96 88 82 76 110 118 125 128 118 91 
38 32 M 74 173 24.7 1 1 > 6.5 70 84 98 90 88 85 131 125 145 128 129 135 
39 50 F 74 160 28.9 1 2 > 6.5 68 70 116 104 97 91 140 139 156 141 135 136 
40 48 M 85 165 31.2 1 1 < 6.5 65 74 104 102 88 80 149 132 149 145 131 132 
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                                                                  MASTER CHART (Contd . . . ) 
 
 
DIA. BP MAP SPO2 Intubation Time sec. Base Line    0 min. Before Intubation 2nd min. 
After Intubation 4th min. 6th min. 8th min. 10th min. Base Line    0 min. Before Intubation 2nd min. 
After Intubation 4th min. 6th min. 8th min. 10th min. Base Line    0 min. Before Intubation 2nd min. 
After Intubation 4th min. 6th min. 8th min. 10th min. 74 76 112 85 77 70 89 92 130 104 89 83 100 100 100 100 100 100 17.2 82 72 100 93 98 78 99 91 129 115 121 84 100 100 922 100 100 100 30.6 95 97 113 112 99 84 122 13 132 127 112 103 100 100 100 100 100 100 18.4 90 62 100 78 85 74 117 71 117 97 99 89 100 100 100 100 100 100 18 80 80 58 75 74 72 93 95 84 91 91 89 100 100 98 100 100 100 18.4 94 80 99 94 90 85 112 93 112 112 101 100 100 100 99 100 100 100 17.6 78 78 100 93 58 58 101 99 129 115 102 84 100 100 98 100 100 100 20.4 55 61 94 90 58 56 73 79 112 101 72 71 100 100 100 100 100 100 18.3 85 100 102 100 96 96 106 104 121 130 117 112 100 100 90 100 100 100 29.1 48 72 74 79 80 60 67 78 98 99 97 72 100 100 92 100 100 100 25.1 65 70 83 82 69 62 84 83 102 101 81 77 100 100 99 100 100 100 23.1 83 80 99 105 96 90 102 100 122 126 112 117 100 100 99 100 100 100 28.4 85 80 93 84 86 69 104 100 115 107 103 81 100 100 100 99 100 100 17.9 100 97 99 103 105 112 121 113 122 127 129 130 100 100 99 99 100 100 17.4 120 77 70 100 97 74 95 83 121 113 89 89 100 100 98 99 100 100 2.1 70 65 83 78 65 70 83 83 102 97 83 83 100 100 100 100 100 100 18 80 63 106 10 103 112 95 79 136 136 127 130 100 100 100 100 100 100 22 85 83 112 105 96 100 99 102 136 128 112 117 100 100 97 100 100 100 21.4 69 68 90 65 77 69 81 79 117 83 89 81 100 100 98 99 100 100 18.1 70 77 74 65 83 69 87 89 94 83 102 81 100 100 99 100 100 100 17 89 84 88 78 80 85 10 103 105 97 100 99 100 100 100 100 100 100 17 78 93 90 83 74 74 96 108 117 102 89 94 100 100 100 100 100 100 15.1 96 99 112 97 96 85 112 122 136 115 112 104 100 100 99 100 100 100 14.3 
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62 56 69 68 70 60 77 66 81 79 83 72 100 100 100 100 100 100 15.2 76 70 80 65 76 77 92 83 100 84 92 89 100 100 100 100 100 100 14 74 65 98 97 74 85 94 84 121 105 98 104 100 100 94 98 100 100 20 74 85 96 112 77 85 89 99 95 99 87 99 100 100 100 100 100 100 16.2 69 62 74 83 78 80 81 77 89 102 96 95 100 100 98 100 100 100 15.3 58 58 94 94 90 58 102 184 128 112 101 84 100 100 100 100 100 100 14.3 97 85 112 100 97 78 113 104 136 117 113 99 100 100 100 100 100 100 13.4 70 65 85 76 77 65 83 84 99 92 95 84 100 100 100 100 100 100 15.2 78 78 99 96 855 78 97 99 122 112 104 101 100 100 100 100 100 100 14.1 80 76 78 85 77 74 100 92 99 104 95 94 100 100 95 99 100 100 22.1 79 101 93 89 83 86 97 116 115 110 102 103 100 100 100 100 100 100 17.2 80 80 103 98 93 83 101 97 127 121 115 102 100 100 100 100 100 100 13.9 71 75 83 78 77 74 91 81 102 97 89 89 100 100 98 100 100 100 21.1 76 65 77 74 65 60 92 83 95 94 84 72 100 100 100 100 100 100 14.1 78 77 90 74 85 86 99 95 117 94 99 103 100 100 100 100 100 100 15.2 88 89 112 96 58 58 105 108 136 112 102 84 100 100 100 100 100 100 17.6 93 84 95 90 83 82 115 103 122 117 102 101 100 100 100 100 100 100 13.2 
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                                                                 MASTER CHART (Contd . . .) 
 
Airway Trauma Yes/No DRUG GIVEN 
                       COMFORT SCORES      SEDATION                 
SCALE 
 ALERTNESS CALMNESS RESPIRATORY RESPONSE CRYING PHYSICAL MOVEMENT MUSCLE TONE FACIAL TENSION TOTAL  
CALMNESS RESPIRATORY 
CRYING PHYSICAL MUSCLE FACIAL     TOTAL    (OUT OF 5)  (OUT OF 5) RESPONSE (OUT OF 5) MOVEMENT TONE TENSION (OUT OF 35)       (OUT OF 5)   (OUT OF 5) (OUT OF 5) OUT OF 5)   NO FENT,MIDAZ 1                 3.00  2 3 2 1 2 3 13 YES FENT,MIDAZ 2                 2.00  2 3 2 2 2 3 14 NO FENT,MIDAZ 2                 2.00  2 3 4 1 2 2 14 NO FENT,MIDAZ 1                 2.00  3 3 3 2 3 2 16 NO FENT,MIDAZ 1                 2.00  3 4 2 1 3 2 15 NO FENT,MIDAZ 3                 3.00  1 4 3 2 1 1 12 NO FENT,MIDAZ 1                 3.00  3 4 1 3 1 1 13 NO FENT,MIDAZ 1                 3.00  2 3 1 3 3 3 15 NO FENT,MIDAZ 3                 3.00  3 3 1 1 3 2 13 YES FENT,MIDAZ 2                 2.00  2 3 4 2 3 3 17 NO FENT,MIDAZ 2                 3.00  3 4 4 1 1 2 15 NO FENT,MIDAZ 1                 3.00  2 4 2 2 2 2 14 NO FENT,MIDAZ 1                 2.00  2 4 2 1 2 2 13 NO FENT,MIDAZ 1                 2.00  2 3 2 2 3 1 13 NO FENT,MIDAZ 1                 3.00  2 3 2 1 3 1 12 
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NO FENT,MIDAZ 3                 2.00  1 3 2 2 3 1 12 NO FENT,MIDAZ 1                 2.00  1 3 2 1 2 2 11 YES FENT,MIDAZ 1                 3.00  3 3 3 2 2 2 15 NO FENT,MIDAZ 1                 2.00  2 2 3 1 1 2 11 NO FENT,MIDAZ 2                 2.00  2 2 3 2 1 2 12 NO DEXMED 2                 3.00  1 2 1 1 1 1 7 NO DEXMED 2                 3.00  1 2 1 2 1 1 8 NO DEXMED 2                 2.00  2 2 1 2 1 2 10 NO DEXMED 2                 3.00  1 2 1 1 1 2 8 NO DEXMED 2                 3.00  1 2 1 1 1 1 7 NO DEXMED 1                 2.00  2 2 1 1 1 1 8 NO DEXMED 3                 3.00  2 3 2 2 2 1 12 NO DEXMED 3                 3.00  1 2 1 2 2 1 9 NO DEXMED 3                 2.00  2 2 1 1 2 2 10 YES DEXMED 2                 3.00  1 2 1 1 2 1 8 NO DEXMED 2                 2.00  1 2 1 1 1 2 8 NO DEXMED 2                 3.00  1 2 1 3 1 1 9 YES DEXMED 2                 2.00  1 2 1 1 1 2 8 NO DEXMED 2                 3.00  2 2 1 1 1 1 8 NO DEXMED 2                 3.00  3 2 1 1 1 1 9 NO DEXMED 2                 2.00  3 2 1 1 2 1 10 NO DEXMED 2                 2.00  1 2 1 1 1 2 8 NO DEXMED 2                 2.00  1 3 1 2 1 2 10 NO DEXMED 2                 2.00  1 2 2 1 1 2 9 NO DEXMED 3                 2.00  1 2 1 2 2 2 10 
 
 
